Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Last month, a second phase 3 blow for Marinus Pharmaceuticals prompted the Pennsylvania-based drugmaker to turn an eye toward ...

While personally “disappointed” about the election’s outcome, current FDA Commissioner Robert Califf, M.D., has laid out the ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

Zimmer Biomet has hired The Terminator to tell the world that “if you rest, you rust.” The manufacturer of orthopedic medtech ...

Despite generic headwinds to Xarelto and challenges across different sectors of the conglomerate suggesting “twists and turns ...

After a series of acquisitions and an activist investor’s accusation of overspending, Pfizer is exploring an opportunity to ...

In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals’ bid to win full approval ...

Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...

AstraZeneca on Tuesday revealed that it’s adding $2 billion more to its current outlay in the U.S., representing a total ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...